Trial Information
Current as of June 26, 2025
Not yet recruiting
Keywords
ClinConnect Summary
The Vitaccess Real CIDP Registry is a long-term study designed to better understand Chronic Inflammatory Demyelinating Polyneuropathy (CIDP), a condition that affects the nerves and can lead to weakness and other symptoms. Over the next 10 years, this registry will collect information from around 300 patients in the US and Europe about their experiences with CIDP, including how it affects their daily lives and the treatments they receive. Participants will share their own health information, which will be linked to their medical records to create a comprehensive view of CIDP.
To join the study, participants must be at least 18 years old, have a confirmed diagnosis of CIDP from a neurologist, and live in the US, UK, or Germany. They also need to have access to a smartphone, tablet, or computer and be willing to provide consent in their preferred language. The study is not currently recruiting, but when it begins, participants can expect to share their experiences, which will help improve understanding and treatment of CIDP for everyone affected by this condition.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Adult (age ≥18 years) with a clinically confirmed diagnosis of CIDP by their treating neurologist
- • Resident in the US, UK or Germany
- • Access to a smartphone/tablet/computer/laptop
- • Willing and able to provide informed consent in their local language to take part in the study
- Exclusion Criteria:
- • None
About Vitaccess Ltd
Vitaccess Ltd. is a pioneering clinical trial sponsor specializing in innovative digital health solutions that enhance patient engagement and streamline data collection in clinical research. With a focus on leveraging technology to improve the efficiency and effectiveness of clinical trials, Vitaccess employs advanced methodologies, including real-world evidence and patient-reported outcomes, to generate meaningful insights that inform healthcare decision-making. The company's commitment to collaboration and transparency ensures the delivery of high-quality data, ultimately contributing to the acceleration of drug development and improved patient care.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported